STAT· @statnews · X·· 2026-10-16精选AI 评分62
AI 导读
欧洲监管机构已推荐批准RevMed的Rasonque用于胰腺癌。EMA表示此次审评用时不到150天,而标准审评通常持续一年。
推荐理由
EMA对RevMed胰腺癌药物给出批准推荐,审评用时不到150天,可与标准审评周期对照理解其节奏。
正文
European regulators have now recommended the approval of RevMed's Rasonque for pancreatic cancer.
The European Medicines Agency said the review took less than 150 days, compared to a standard review, which often lasts a year. https://trib.al/PfSmaqM
来源:STAT · x.com